Active Ingredient History
Etomidate (AMIDATE®) is an imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It is intended for the induction of general anesthesia by intravenous injection. Etomidate (AMIDATE®) is also indicated for the supplementation of subpotent anesthetic agents, such as nitrous oxide in oxygen, during maintenance of anesthesia for short operative procedures such as dilation and curettage or cervical conization. It also produces a unique toxicity among anesthetic drugs - inhibition of adrenal steroid synthesis that far outlasts its hypnotic action and that may reduce survival of critically ill patients. The major molecular targets mediating anesthetic effects of etomidate (AMIDATE®) in the central nervous system are specific gamma-aminobutyric acid (GABA) type A receptor subtypes. The R(+) isomer of etomidate is 10 times more potent than its S(-) isomer at potentiating GABA-A receptor activity. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Pain (approved 1982)
Abortion, Induced (Phase 4)
Acne Vulgaris (Phase 4)
Airway Management (Phase 4)
Anesthesia (Phase 4)
Anesthesia, General (Phase 4)
Anesthetics, General (Phase 1)
Cholangiocarcinoma (Phase 4)
Choledochal Cyst (Phase 4)
Choledocholithiasis (Phase 4)
Congenital Abnormalities (Phase 4)
Conscious Sedation (Phase 4)
Coronary Artery Bypass (Phase 4)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
Critical Illness (Phase 2/Phase 3)
Delirium (Phase 4)
Depression (Phase 4)
Electroconvulsive Therapy (Phase 4)
Etomidate (Phase 4)
Fractures, Bone (Phase 4)
General Surgery (Phase 4)
Heart Arrest (Phase 4)
Heart Valve Diseases (Phase 4)
Hemodynamics (Phase 4)
Hepatic Insufficiency (Phase 1)
Hypertension (Phase 3)
Hypoadrenocorticism, Familial (Phase 4)
Hysteroscopy (Phase 4)
Infusions, Intravenous (Phase 4)
Intubation (Phase 4)
Lung Diseases (Phase 4)
Magnetic Resonance Spectroscopy (Phase 4)
Mitral Valve Insufficiency (Phase 4)
Myoclonus (Phase 4)
Oxidative Stress (Phase 4)
Pancreatic Neoplasms (Phase 4)
Pancreatitis (Phase 4)
Postoperative Cognitive Complications (Phase 4)
Postoperative Complications (Phase 4)
Respiratory Insufficiency (Phase 2)
Shoulder Dislocation (Phase 4)
Stroke (Phase 3)
Thoracic Surgery (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
